Your search history is turned on.
Date: April 29, 2024 Jurisdictions: All jurisdictions
Sona's Cancer Therapy Creates a Systemic Immune Response in Murine Breast Cancer Model Halifax, Nova Scotia--(Newsfile Corp. - April 29, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces further results from the triple negative breast cancer murine model portion of its current research study at Dalhousie University (the "Study") which confirms that the previ...
Date: April 12, 2024 Jurisdictions: All jurisdictions
Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce further positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). The Company was provided with data from...
Date: April 8, 2024 Jurisdictions: All jurisdictions
Sona Nanotech Secures Grant Funding to Support Intellectual Property Strategy and Development Halifax, Nova Scotia--(Newsfile Corp. - April 8, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces that it has been approved for funding totaling approximately $40,000 to support the development of its intellectual property portfolio. The Company is receiving adv...
Date: March 28, 2024 Jurisdictions: All jurisdictions
Microsoft Word - Sona Q1 2024 MDA - Final Sona Nanotech Inc. Management Discussion and Analysis Three-months ended January 31, 2024 This Management Discussion and Analysis ("MD&A") provides a review of the performance of Sona Nanotech Inc. ("Sona or the Company) and should be read in conjunction with the unaudited condensed interim financial stat...
Microsoft Word - Sona Nanotech Inc 52null109FV2 -Rob Randall - March 28, 2024 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Robert Randall, Chief Financial Officer of Sona Nanotech Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the interim filings...
Microsoft Word - Sona Nanotech Inc 52null109FV2 - David Regan - March 28, 2024 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, David Regan, Chief Executive Officer of Sona Nanotech Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the interim filings)...
Microsoft Word - Sona Nanotech FS Jan 31 2024 - Final Unaudited Condensed Interim Consolidated Financial Statements of SONA NANOTECH Inc. For the quarters ended January 31, 2024 and 2023 (Expressed in Canadian Dollars) March 28, 2024 Manag...
Date: March 25, 2024 Jurisdictions: All jurisdictions
Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results Halifax, Nova Scotia--(Newsfile Corp. - March 25, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). An update received by the Company indicates that all tumo...
Date: March 21, 2024 Jurisdictions: All jurisdictions
NATIONAL INSTRUMENT 54-101 NATIONAL INSTRUMENT 54-101 CERTIFICATE I, David Regan, President and CEO of Sona nanotech Inc. (the "Issuer"), certify that: 1. I have reviewed the proxy-related materials (as this term is defined in National Instrument 54-101 - Communication with Owners of Securities ("NI 54-101")) of the Issuer dated March 13...
Security Class Holder Account Number Form of Proxy - Annual General Meeting to be held on April 26, 2024 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of their choice, who need not be a holder, to attend and act on their behalf at the meeting or any ...